Ficlatuzumab clinical trials
Also written AV-299 and SCH 900105.
How each study uses ficlatuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ficlatuzumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2015 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 7
AVEO Pharmaceuticals, Inc. (6) · University of Arizona (1) · Dana-Farber Cancer Institute (1) · James J Lee (1) · Beat AML, LLC (1) · C. Babis Andreadis (1) · Julie E. Bauman, MD, MPH (1) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Gemcitabine (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Samalizumab (1) · BI 836858 (1) · Cytarabine (1) · Azacitidine (1) · Enasidenib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test ficlatuzumab, phase 3 first.
- Aug 2027A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell CarcinomaPhase 3 · AVEO Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses ficlatuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as ficlatuzumab (BAML-16-001-S24)
- A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell CarcinomaRecruitingPhase 3AVEO Pharmaceuticals, Inc.NCT06064877Written as Ficlatuzumab
- Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell CarcinomaCompletedPhase 2University of ArizonaNCT03422536Written as Ficlatuzumab
- Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic CancerCompletedPhase 1Dana-Farber Cancer InstituteNCT03316599Written as Ficlatuzumab
- A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive LabelTerminatedPhase 2AVEO Pharmaceuticals, Inc.NCT02318368Written as Ficlatuzumab
- A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaWithdrawnPhase 2AVEO Pharmaceuticals, Inc.NCT04100330Written as Ficlatuzumab
- Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AMLTerminatedPhase 1C. Babis AndreadisNCT02109627Written as Ficlatuzumab
- Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)CompletedPhase 1James J LeeNCT02277197Written as Ficlatuzumab
- Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedPhase 1Julie E. Bauman, MD, MPHNCT02277184Written as Ficlatuzumab
- A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung CancerCompletedPhase 1/2AVEO Pharmaceuticals, Inc.NCT01039948Written as AV-299 + gefitinib
- A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple MyelomaCompletedPhase 1AVEO Pharmaceuticals, Inc.NCT00725634Written as AV-299
- A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver MetastasesCompletedPhase 1AVEO Pharmaceuticals, Inc.NCT00969410Written as AV-299
- SCH-900105 in Recurrent GlioblastomaWithdrawnPhase 1M.D. Anderson Cancer CenterNCT01189513Written as SCH 900105
Codes
What other systems call ficlatuzumab · ClinicalTrials.gg INT006343
- MeSH (NLM) C583360ficlatuzumabOne source NLM
- UNII (FDA) 77E89833TGFICLATUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5446524FiclatuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78844FiclatuzumabOne source FDA
- DrugBank DB11680One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583360 | ficlatuzumab | One source NLM |
| UNII (FDA) | 77E89833TG | FICLATUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5446524 | Ficlatuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78844 | Ficlatuzumab | One source FDA |
| DrugBank | DB11680 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.